businessbriefs
Saved
Companies · Scandals

Sinopharm (company)

1998

A state-owned vaccine developer that delivered peer-reviewed efficacy — and sold 400,520 faulty doses.

Worth your time?3.5/5Yes.Study the whole thing.What works, what does not, who it is for ↓
11:06in productionCh. 1 · State-Owned From Day One/ 11:06 · ceiling 15 min
4 chapters · 11:06Ceiling 15:00

The brief is written and checked. The video joins this page when it is cut.4 chapters · 1 min read · 11:06 planned

Read the brief

Sinopharm is a Chinese state-owned enterprise founded on November 26, 1998. It developed the BBIBP-CorV inactivated virus COVID-19 vaccine, which showed 78.1% efficacy against symptomatic disease and 100% against severe disease in peer-reviewed Phase III trials. In 2009, it merged with China National Biotec Group. Its subsidiary Wuhan Institute of Biological Products was fined in November 2017 for selling 400,520 ineffective DPT vaccines.

CompaniesScandalsChinaVaccinesPhotographyChina across the network →
Chapters & takeaways4
  1. 1:06
    State-Owned From Day One

    Sinopharm is not a startup — it is a 1998 Chinese state-owned holding company built from four legacy pharmaceutical entities.

  2. 2:49
    The Biotec Merger

    The 2009 merger with China National Biotec Group gave Sinopharm direct vaccine R&D capacity — but also inherited its subsidiaries’ track record.

  3. 5:02
    What the Data Says

    BBIBP-CorV achieved 78.1% efficacy in peer-reviewed trials — but interim claims of 86% were never published in JAMA.

  4. 6:54
    The DPT Failure

    In November 2017, a Sinopharm subsidiary sold 400,520 ineffective DPT vaccines — then was fined.

Worth your time?

Yes. Study the whole thing.

3.5/ 5
What works
  • whatWorks
What does not
  • howItActuallyMakes
Study it if
  • public-health-policy-makers
  • regulatory-analysts
  • global-vaccine-distribution-researchers
Skip it if
  • investors-seeking-financial-transparency
  • entrepreneurs-looking-for-business-model-inspiration
The written brief1 min read

What the company or idea is

Sinopharm is a Chinese state-owned enterprise founded on November 26, 1998, as a holding company for four national pharmaceutical and medical device entities.

How it actually makes money

Sinopharm is a Chinese state-owned enterprise. It makes money through pharmaceutical manufacturing, distribution, and vaccine sales — but the material does not specify revenue streams, margins, pricing, or who pays (governments, insurers, individuals).

What works

BBIBP-CorV completed Phase III trials across seven countries with over 60,000 participants. Peer-reviewed JAMA results confirmed 78.1% efficacy against symptomatic disease and 100% against severe disease.

What does not

Sinopharm’s subsidiary sold 400,520 ineffective DPT vaccines in November 2017 and was fined. That failure reveals a gap between its public health mandate and quality control execution.

What to take from it

Sinopharm shows how state-backed biotech can rapidly scale vaccine development and deployment — while carrying legacy liabilities from pre-merger subsidiaries and inconsistent quality enforcement.

Is it worth your time

Yes — if you need to understand how state-owned vaccine developers operate under regulatory scrutiny, commercial pressure, and geopolitical demand. No — if you seek transparency on unit economics, profitability, or independent market validation.

Same desk · Companies4 of 325
10:03
Sanofi2004Sanofi is a French pharmaceutical company founded in 1973. In 2004, it merged with Aventis to form Sanofi-Aventis — a deal driven by scale, not science. It makes money from prescription drugs and vaccines, not breakthroughs. Its strength lies in manufacturing, marketing, and regulatory reach — not discovery velocity.
9:48
Serum Institute of India1966Serum Institute of India is the world's largest vaccine manufacturer by volume — a fact rooted in production capacity and multilateral procurement, not IP, pricing power, or domestic dominance. Its business model depends on high-volume, low-margin contracts with global health institutions. Nothing in the source material confirms profitability, cost structure, or innovation claims. It is infrastructure masquerading as enterprise.
11:36
Shanghai Pharmaceuticals1952Shanghai Pharmaceuticals is a distribution-first firm that used acquisition — not innovation — to become China’s largest pharmaceutical company and second-largest distributor. Its dual listing and Fortune 500 rank reflect scale and access, not clinical or commercial leadership beyond borders. Its R&D spend is modest in absolute terms and does not signal a pivot toward proprietary drug development.
12:05
Eli Lilly and CompanyEli Lilly · 1875Eli Lilly and Company is a foundational case in how business infrastructure — not just discovery — creates pharmaceutical power. Its early bets on quality control, prescription gatekeeping, and regulation were deliberate, profitable, and durable. The sources confirm no modern financials or valuations, so analysis must stay anchored in its documented methods and milestones.
Up next in Business

SIX Swiss Exchange

1873 · 10:00

A national exchange built on merger, not markets — and still running the same core code that made it first in line.

Next brief →Back to Companies
10:00